In a randomized clinical trial, vixarelimab demonstrates dose-dependent, long-term safety and efficacy in patients with prurigo nodularis.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/first-class-monoclonal-antibody-safe-effective-patients-2025a1000zg6?src=rss
Author :
Publish date : 2025-12-17 16:10:00
Copyright for syndicated content belongs to the linked Source.
